Lexaria's DehydraTECH-CBD lowers blood pressure in 66-patient hypertension study

Lexaria Bioscience Corp.

Systolic BP reduced up to 5.60 mmHg (p<0.001) over 5 weeks vs. placebo; no serious adverse events.
BP reduction sustained for full study duration, exceeding cardiovascular risk reduction thresholds (4.6/2.2 mmHg).
Additive BP lowering observed in patients already on standard antihypertensive therapy.
Study used 225-450 mg/day DehydraTECH-CBD with zero serious adverse events and no liver enzyme changes.
Results support planned Phase Ib IND study with FDA; full results to be submitted for peer review.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.